This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

Feuerstein graduated from Emory University with a bachelor's degree in political science.

Adam Feuerstein
By This Author:
Page 3 of 579

Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off

By Adam Feuerstein

Let's look back at the stock performance of biotech companies issuing the worst, most pandering press releases from January 2014.

11:00AM 12/02/14

Avanir Fetches $3.5B From Japan's Otsuka for Reformulated Cough Syrup

By Adam Feuerstein

The Japanese drugmaker is trying to shore up its product pipeline ahead of April 2015 when patents on its best-selling schizophrenia drug Abilify expire.

09:13AM 12/02/14

Future of Exelixis Cancer Drug Dims Further With Second Failed Prostate Cancer Study

By Adam Feuerstein

All too often, promising results from phase II studies don't pan out when larger, confirmatory phase III studies are conducted. That's exactly what happened to Exelixis.

11:37AM 12/01/14

December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey

By Adam Feuerstein

A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for health care investors.

06:00AM 11/26/14

Ousted Retrophin CEO Sold Stock While Urging Investors to Buy

By Adam Feuerstein

Martin Shkreli, the ousted CEO of Retrophin, received $3 million from selling company stock but delayed disclosure for two months, a new SEC filing shows.

12:41PM 11/25/14

Galena, Shunned by Wall Street, Forced to Seek Pricey Vulture Financing

By Adam Feuerstein

The scandal-ridden Galena, still under active SEC investigation, was unable to muster sufficient interest from institutional investors.

09:39AM 11/24/14

BioMarin Expands Reach by Buying Prosensa for Up to $840 Million

By Adam Feuerstein

BioMarin is betting that its experience in securing approvals for "orphan-disease" drugs can help Prosensa win approval for drisapersen, an experimental treatment for Duchenne muscular dystrophy.

06:34AM 11/24/14

Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

06:00AM 11/21/14

Royalty Pharma's $3.3 Billion Transaction is Bullish for Vertex Pharma

By Adam Feuerstein

The $3.3 billion paid by Royalty Pharma to the Cystic Fibrosis Foundation to acquire royalty rights to Vertex Pharmaceuticals' cystic fibrosis drugs suggests investors are under-estimating peak sales.

01:25PM 11/19/14

Clovis Lung Cancer Update Swings Momentum to Rival, Slightly

By Adam Feuerstein

Healthcare investors are watching closely the race between Clovis and AstraZeneca to develop competing, targeted lung cancer drugs.

09:38AM 11/19/14

Page 3 of 579

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs